Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of QLS4131 combination therapy in malignant plasma cell neoplasms
CTR20261752Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS4131 in multiple myeloma (MM), plasma cell leukaemia (PCL), light-chain amyloidosis, plasma cell malignancies, sponsored by Qilu Pharmaceutical. Started May 2026; status: active.
02
Drugs
QLS4131
03
Conditions
multiple myeloma (MM)plasma cell leukaemia (PCL)light-chain amyloidosisplasma cell malignancies
Beyond the preview
Go deeper on CTR20261752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261752.